Amgen’s Bufferless Eylea Biosimilar Again Knocks Back Regeneron’s Injunctive Bid
‘A Substantial Question Of Noninfringement,’ US Federal Circuit Finds As It Affirms On Appeal
Amgen’s biosimilar aflibercept formulation is keeping it head and shoulders above other would-be Eylea biosimilar competitors, while continuing to frustrate originator Regeneron’s push to block sales of the product while it battles Amgen over alleged infringement of a key US patent.
